Kyverna Therapeutics Inc

Kyverna Therapeutics, Inc. is a cell therapy clinical-stage biotechnology company, which engages in the provision of treatments and potential cures for serious autoimmune diseases. The company is headquartered in Emeryville, California and currently employs 134 full-time employees. The company went IPO on 2024-02-08. The Company’s lead chimeric antigen receptor (CAR) T-cell therapy candidate, KYV-101, is advancing through clinical development with Phase II trials for stiff person syndrome and myasthenia gravis, and two ongoing multi-center Phase I/II trials for patients with lupus nephritis. KYV-101 is an autologous, fully human CD19 CAR T-cell product candidate incorporating highly potent CD28 co-stimulation. The firm is also harnessing investigator-initiated trials and other KYSA studies, including in multiple sclerosis and systemic sclerosis, to inform the next priority indications for the Company to advance into late-stage development. Its pipeline includes next generation CAR T-cell therapies in both autologous and allogeneic formats with properties intended to be well suited for use in B cell-driven autoimmune diseases.